← Leaderboards
Christopher M Heaphy
Johns Hopkins University
$1,066,793
Attributed
$2,133,585
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $781.7K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,133,585 · 2
By mechanism
R01$1,663,456 · 1
R21$470,129 · 1
Top collaborators
- Alan Keith Meeker3 shared
- Ruben Dries2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Richard F. Ambinder$9,273,650
- Kenneth J. Pienta$43,861,680
- Martin G Pomper$38,517,075
- Alan Keith Meeker$5,318,574
- Angelo Michael De Marzo$8,441,808
Others in their field
Other Rising Stars on “Prognostic”
- Thomas K Karikari · Wake Forest University Health Sciences$12,972,426
- Sabrina Paganoni · Massachusetts General Hospital$9,673,541
- Suma Babu · Massachusetts General Hospital$9,673,541
- James Cappo · National Jewish Health$9,298,220
- Christopher J. Lindsell · Vanderbilt University Medical Center$5,239,592
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
Research focus
PrognosticInnovationPatternTreatment ResponseCell TypeImageMalignant NeoplasmsBiologyPrognostic MarkerTumorPrognosisCancer CellCellsCategoriesCancer Therapy Evaluation ProgramImage AnalysisBostonBiochemicalImmunofluorescence ImmunologicDistant MetastasisDiagnosisEventClinicCox Models
Grant awards (5)
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy$534,909
R01 · FY2025 · CA
Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors$246,752
R21 · FY2025 · CA · contact PI
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy$505,583
R01 · FY2024 · CA
Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors$223,377
R21 · FY2024 · CA · contact PI
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy$622,964
R01 · FY2023 · CA